UNITED STATES SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D.C.  20549

                                   FORM 10-Q

(Mark One)
X[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     - --                                                                   
   EXCHANGE ACT OF 1934
For the quarterly period ended                November 2, 1996
                               ------------------------------------------------May 3, 1997
                              _________________________________________

                                       OR

[_]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF --THE SECURITIES
     EXCHANGE ACT OF 1934
For the transition period from             to
                              -------------   -------------_____________  _____________

Commission file number                   0-13200
                      --------------------------------------------------------__________________________________________________________

                                      Astro-Med, Inc.
- -------------------------------------------------------------------------------________________________________________________________________________________
                  (Exact name of registrant as specified in its charter)


           Rhode Island                                   05-0318215
- -------------------------------------------------------------------------------________________________________________________________________________________
  (State or other jurisdiction of                      (I.R.S. Employer
   incorporation or organization)                     Identification No.)

         600 East Greenwich Avenue, West Warwick, Rhode Island   02893
- -------------------------------------------------------------------------------________________________________________________________________________________
              (Address of principal executive offices)          (Zip Code)

                                (401) 828-4000
- -------------------------------------------------------------------------------________________________________________________________________________________
             (Registrant's telephone number, including area code)

                           ________________________


    Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.   Yes  X [X].  No  [_].
                                               ---     ---

    Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

                Common Stock, $.05 Par Value - 4,966,1834,886,635 shares
                 (excluding treasury shares) as of October 25, 1996May 23,1997

                                      -1-

 
                                ASTRO-MED, INC.
                                     INDEX

                                                              Page No.
                                                              --------
Part I.  Financial Information:

  Consolidated Balance Sheets -
    January 31, 19961997 and November 2,1996......................May 3, 1997. ........................   3

  Consolidated Statements of Income -
    Three Months Ended October 28, 1995May 4, 1996 and November 2, 1996..May 3, 1997............   4

  Consolidated Statements of Income
    Nine Months Ended October 28, 1995 and November 2, 1996...   5

  Consolidated Statements of Cash Flows -
    NineThree Months Ended October 28, 1995May 4, 1996 and November 2, 1996...   6May 3, 1997............   5

  Notes to Consolidated Financial Statements -
    November 2, 1996..........................................   7May 3, 1997...............................................   6

  Management's Discussion and Analysis of Financial
    Condition and Results of Operations.......................   8,97

Part II. Other Information...................................   10,11

  Item 6.  Exhibits and Reports on Form 8-K



 

                                       2Information....................................   8,9



                                      -2-

 
Part I.  FINANCIAL INFORMATION
                                ASTRO-MED, INC.
                     UNAUDITED CONSOLIDATED BALANCE SHEETS
January 31, November 2,May 3, ASSETS 1996 19961997 1997 ------------ ------------ (Unaudited) CURRENT ASSETS Cash and Cash Equivalents.................. $ 2,033,7136,561,184 $ 6,138,9427,157,818 Securities Available for Sale.............. 6,659,828 6,942,4977,099,358 7,185,894 Accounts Receivable, Net................... 8,318,005 8,331,1168,311,736 7,698,071 Inventories................................ 12,533,553 11,628,88910,361,505 10,392,399 Prepaid Expenses and Other Current Assets.. 1,424,757 1,402,3901,441,505 1,661,549 ----------- ----------- Total Current Assets..................... 30,969,856 34,443,83433,775,288 34,095,731 PROPERTY, PLANT AND EQUIPMENT 17,063,855 17,196,31017,046,969 17,168,045 Less Accumulated Depreciation.............. (8,350,722) (9,189,923)(8,986,149) (9,342,068) ----------- ----------- 8,713,133 8,006,3878,060,820 7,825,977 OTHER ASSETS Excess of Cost Over Net Assets Acquired.... 1,012,693 985,459976,384 967,310 Other...................................... 1,607,049 532,838508,935 782,640 ----------- ----------- 2,619,742 1,518,2971,485,319 1,749,950 ----------- ----------- $42,302,731 $43,968,518$43,321,427 $43,671,658 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts Payable........................... $ 2,136,8251,614,986 $ 2,528,6462,041,006 Accrued Compensation....................... 1,200,082 880,0031,115,026 1,371,972 Accrued Expenses........................... 730,345 1,194,3951,318,103 899,850 Income Taxes............................... 432,540 1,072,153819,535 937,950 Current Maturities of Long-Term Debt....... 50,000 50,00097,706 98,860 ----------- ----------- Total Current Liabilities................ 4,549,792 5,725,1974,965,356 5,349,638 LONG-TERM DEBT, Less Current Maturities..... 175,000 125,000258,135 227,706 EXCESS OF NET ASSETS ACQUIRED OVER COST..... 761,879 598,619544,199 489,779 DEFERRED INCOME TAXES....................... 834,754 834,754794,895 794,895 STOCKHOLDERS' EQUITY Preferred Stock, $10 Par Value, Authorized 100,000 Shares, None Issued.... Common Stock, $.05 Par Value, Authorized 13,000,000 Shares, Issued 5,123,3105,136,737 and 5,135,5785,137,530 Shares, Respectively........ 256,166 256,779256,837 256,881 Additional Paid-In Capital................. 5,554,100 5,615,5715,624,239 5,631,070 Retained Earnings.......................... 31,079,623 32,385,27232,772,044 33,202,587 Treasury Stock, at Cost (103,066(209,395 Shares and 169,395250,895 Shares, Respectively)......... (902,169) (1,468,111)(1,804,986) (2,118,821) Cumulative Translation Adjustment.......... (38,368) (82,176)(76,649) (131,747) Net Unrealized Gain (Loss) on Securities Available for Sale........................ 31,954 (22,387)(12,643) (30,330) ----------- ----------- 35,981,306 36,684,94836,758,842 36,809,640 ----------- ----------- $42,302,731 $43,968,518$43,321,427 $43,671,658 =========== ===========
3-3- ASTRO-MED, INC. UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended -------------------------- October 28, November 2, 1995------------------------- May 4, May 3, 1996 ------------ ------------1997 ----------- ----------- Net Sales.................................... $10,823,820 $11,110,514Sales...................................... $10,489,822 $11,706,507 Cost of Sales................................. 6,587,639 6,572,197 ----------Sales.................................. 6,531,526 7,202,596 ----------- ----------- Gross Profit.................................. 4,236,181 4,538,317Profit................................... 3,958,296 4,503,911 Costs and Expenses: Selling, General and Administrative......... 3,246,100 3,017,702Administrative.......... 3,351,265 3,139,098 Research and Development.................... 591,821 643,092 ----------Development..................... 605,921 709,328 ----------- 3,837,921 3,660,794 --------------------- 3,957,186 3,848,426 ----------- ----------- Operating Income.............................. 398,260 877,523Income............................... 1,110 655,485 Other Income (Expense): Investment Income........................... 84,287 157,489Income............................ 519,039 194,199 Interest Expense............................ (429) (3,349)Expense............................. (3,955) (3,239) Other, Net.................................. (2,747) 41,665 ---------- ----------- 81,111 195,805 ---------- ----------- Income before Income Taxes.................... 479,371 1,073,328 Provision for Income Taxes.................... 199,000 389,620 ---------- ----------- Net Income.................................... $ 280,371 $ 683,708 ========== =========== Earnings Per Common Share..................... $.06 $.14 ========== =========== Weighted Average Number of Common and Common Equivalent Shares Outstanding............... 5,097,232 5,014,191 ========== =========== Dividends Declared Per Common Share........... $.03 $.03 ========== ===========
4 ASTRO-MED, INC. UNAUDITED CONSOLIDATED STATEMENTS OF INCOME Nine Months Ended --------------------
October 28, November 2, 1995 1996 ------------ ------------ Net Sales.................................... $32,566,709 $32,779,109 Cost of Sales................................ 19,473,919 19,879,552Net................................... 17,917 (24,018) ----------- ----------- Gross Profit................................. 13,092,790 12,899,557 Costs and Expenses: Selling, General and Administrative........ 10,126,673 9,500,079 Research and Development.................... 1,811,923 1,846,599 ----------- ----------- 11,938,596 11,346,678 ----------- ----------- Operating Income.............................. 1,154,194 1,552,879 Other Income (Expense): Investment Income........................... 259,455 828,197 Interest Expense............................ (17,705) (15,366) Other, Net.................................. 234,363 81,200 ----------- ----------- 476,113 894,031533,001 166,942 ----------- ----------- Income before Income Taxes.................... 1,630,307 2,446,910Taxes..................... 534,111 822,427 Provision for Income Taxes.................... 482,000 733,620Taxes..................... (91,000) (244,055) ----------- ----------- Net Income ..................................Income..................................... $ 1,148,307443,111 $ 1,713,290578,372 =========== =========== Earnings Per Common Share.....................$ .23 $ .34Share...................... $.09 $.12 =========== =========== Weighted Average Number of Common and Common Equivalent Shares Outstanding............... 5,099,676 5,025,371Outstanding................ 5,038,008 4,964,505 =========== =========== Dividends Declared Per Common Share...........$ .09 $ .09Share............ $.03 $.04 =========== ===========
5-4- ASTRO-MED, INC. UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
NineThree Months Ended -------------------------- October 28, November 2, 1995------------------------ May 4, May 3, 1996 ------------ ------------1997 ----------- ----------- Cash Flows from Operating Activities: Net Income..................................... $1,148,307 $ 1,713,290443,111 $ 578,372 Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities: Depreciation and Amortization.............. 961,223 703,175204,006 310,573 Gain on Sale of Investment................. (416,090) Deferred Income Taxes...................... 108,965 Other...................................... (41,773)(72,785) Changes in Assets and Liabilities: Decrease in Accounts Receivable.......... 84,900 60,389 (Increase) decrease in Inventories..... (1,104,524) 904,664 [Decrease(increase)in] Other............. 613,345 (95,881) (Decrease) increase inReceivable...................... 1,670,259 613,665 Inventories.............................. (171,833) (30,894) Other.................................... 9,034 (580,285) Accounts Payable and Accrued Expenses............. (559,567) 535,791 (Decrease) increase in AccruedExpenses.... (189,403) 264,713 Income Taxes............................. (91,333) 639,61352,787 118,415 ---------- --------------------- Total Adjustments...................... (28,764) 2,331,6611,158,760 623,402 Net Cash Provided by Operating Activities....................... 1,119,543 4,044,9511,601,871 1,201,774 Cash Flows from Investing Activities: Proceeds from Sales of Securities Available for Sale........................... 2,696,728 1,487,684 Purchases of Securities Available for Sale................................... (2,190,401) (282,669)Sale..................................... (77,216) Proceeds from Sale of Building................. 515,935 Additions to Property, Plant and Equipment..... (829,192) (649,455)(146,150) (121,076) ---------- --------------------- Net Cash (used) Provided by Investing Activities....................... (322,865) 1,071,4951,780,253 (121,076) Cash Flows from Financing Activities: Payments of Long-Term Debt..................... (350,000) (50,000) Short-Term Borrowing from Bank................. 500,000(25,000) (29,275) Proceeds from Common Shares Issued Under Employee Benefit Plans................. 84,102 62,08415,933 6,875 Purchases of Treasury Stock.................... (176,254) (565,942)(434,379) (313,835) Dividends Paid................................. (452,992) (457,359)(150,065) (147,829) ---------- --------------------- Net Cash (Used) by Financing Activities...... (395,144) (1,011,217)(593,511) (484,064) Net Increase/(Decrease)Increase in Cash and Cash Equivalents.................................... 401,534 4,105,2292,788,613 596,634 Cash and Cash Equivalents, Beginning of Period... 1,107,191Period............................ 2,033,713 6,561,184 ---------- -------------------- Cash and Cash Equivalents, End of Period......... $1,508,725 $ 6,138,942$4,822,326 $7,157,818 ========== ===================== Supplemental Disclosures of Cash Flow Information: Cash Paid During the Period for: Interest................................... $ 21,9428,643 $ 24,4777,099 Income Taxes............................... $ 260,86938,224 $ 69,85533,456 ========== ==========
6-5- ASTRO-MED, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS November 2, 1996May 3, 1997 Note 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) The accompanying financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, and reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. All accounting policies have been applied in a manner consistent with prior periods. These financial statements do not include all disclosures associated with annual financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company's annual report on Form 10-K for the year ended January 31, 1996.1997. (b) Earnings per common share are computed based on the weighted average number of common shares and common share equivalents outstanding during each period. Common share equivalents include the dilutive effect of certain stock options under the treasury stock method. Fully diluted earnings per share have not been separately presented since they would not be materially different. In February, 1997, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard (SFAS) No. 128, Earnings Per Share, which supercedes APB Opinion 15. The Statement's objective is to simplify and harmonize the computation of earnings per share and to make the U.S. standard for computing earnings per share more compatible with the EPS standards of other countries and with that of the International Accounting Standards Committee. As required by SFAS No. 128, the Company will adopt this statement for the fiscal year ending January 31, 1998. Pro-Forma basic and diluted earnings per share had the Company adopted SFAS No. 128 for the first quarter of fiscal year 1997 were equal to $.09. Pro-Forma basic and diluted earnings per share had the Company adopted SFAS No. 128 for the first quarter of fiscal year 1998 were equal to $.12. Note 2 - INVENTORIES Inventories are stated at the lower of cost (first-in, first-out) or market and include material, labor and manufacturing overhead. The components of inventories were as follows:
January 31, November 2, 1996 1996May 3 1997 1997 ----------- ----------- Materials and Supplies.. $ 6,460,7305,558,216 $ 6,289,6585,732,069 Work-In-Process......... 1,381,220 1,234,000779,337 933,770 Finished Goods.......... 4,691,603 4,105,2314,023,952 3,726,560 ----------- ----------- $12,533,553 $11,628,889$10,361,505 $10,392,399 =========== ===========
7-6- ASTRO-MED, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Results of Operations: - ---------------------- Net Sales rose 12% in the Company's third fiscalfirst quarter increased 3%over the prior year's first quarter. The increase was due to an 18% increase over the prior year fiscal third quarter. Growth was most evidentin the domestic channels. International sales declined 5% from last year as the strength of the US dollar tempered the local currency growth realized in our domestic channels where Sales increased 7% over last year. Internationally, volume was comparable to last year although our Asian, UK and ItalianEuropean markets. All three product groups reported sales revenues experienced growth. The Company continues to expand new product offerings during the third quarterincrements with the Printing Systems including Sundance, Data Acquisition SystemsBarcode and Astro-DAQ. DemandGrass Products Groups posting single digit growth rates and the Core Products Group reporting double digit growth rates. Gross Profit percentages were 39% in the first quarter as compared to 38% in the prior year first quarter. The improved percentage was healthy for both the Company's traditional core recorderresult of an improved mix of sales of higher margin products as well as the Grass Instrument linesales volume itself which increased the factory overhead absorption rate. Selling, Research & Development and General & Administrative expenses declined 3% from last year's first quarter. These operating expenses consumed 33% of products.the first quarter's sales as compared to last year's rate of 38%. Most of the reduction in spending results from lower professional fees. The third quarter sales mix generated $4,538,000 in Gross Profits for the three month period. This resultCompany's Other Income was 7% higherlower this year than last year's third quarter and producedfirst quarter. The decrease results from a yield of 40.8% as compared withone time gain reported last year from the prior year's mark of 39.1%. The Company has improved its Gross Profit Percent during each quartersale of the current fiscal year toCompany's investment position in a nine month Gross Profit Percent of 39.4%. Although this level is behind last year's 40.2%,limited partnership. Financial Condition: - ------------------- The Company's Assets increased 1% in the Company expects the improvement trend to continue. Astro-Med's quarterly operating expenses of $3,660,000 were 5% lower than last year. This result is consistent with this year's pace in spending which is also 5% behind last year's level for nine months, as the Company has reduced its selling expenses and administrative personnel from prior year levels. Other Income was $196,000quarter. Working Capital dollars declined slightly in the quarter against last year's results of $81,000 for the same quarter. This year's improvement is a result of additional interest earned on the Company's expanded investment portfolio. After nine months the Company has other income of $894,000 in comparison to last year's $476,000. The improvement is attributable$28,745,000. Cash and Cash Equivalents rose $597,000 to gains on sale of investments and interest income. Net Income in the quarter was $684,000 generating a 6.2% return on sales. This quarter's income was better than last year's 3rd quarter by $404,000 or 144%. The Company has earned $1,713,000 in Net Income after nine months of the current fiscal year against a prior year result of $1,148,000 for the same time frame. Financial Condition: - -------------------- The Company increased its cash position by $937,000 in the 3rd quarter. Normal operations generated $1,563,000 in cash available while Investing requirements of $359,000 including capital expenditures and Financing activities of $267,000 including (dividends and treasury stock) purchases consumed cash. The Net Working Capital balances rose $513,000 in the three months to $28,718,000$7,158,000 at quarter's end. Accounts Receivable decreased 7% to $7,698,000, whereas Inventories were virtually flat at $10,392,000. Long Term Debt representing capital lease obligations decreased by $30,000 in accordance with the pay down schedule of these agreements. The growth in the accounts receivable investment was the primary factor. 8 The Company's cash and cash equivalent balances have risen by $4,105,000Company purchased 41,500 shares of its Common Stock during the current fiscal year. The result is traceablequarter in accordance with its Common Stock repurchase plan. Shareholders' Equity increased by 3% during the period to Operations which have produced $4,033,000 in operating cash flow while$36,809,000 at the Company's Investing and Financing activities have offset their respective cash flows. 9quarter's end. -7- PART II. OTHER INFORMATION Item 4. Results of Votes of Security Holders An Annual Meeting of Shareholders of the registrant was held May 20, 1997. A proposed stock option plan was presented to the shareholders for their approval. Also, shareholders were asked to elect a Board of Directors to serve until the next Annual Meeting of Shareholders or until their successors are elected and qualified. The Company's 1997 Incentive Stock Option Plan was approved by the following vote: For--3,541,689; Against--71,559; Abstain--47,151. In an uncontested election, nominees for directors were elected by the following votes:
Name of Nominee Votes Votes for Director For Withheld - ------------------------ --------- -------- Albert W. Ondis 4,644,638 11,739 Everett V. Pizzuti 4,646,088 10,289 Jacques V. Hopkins 4,645,638 10,739 Hermann Viets 4,646,088 10,289 Neil K. Robertson 4,646,088 10,289
Item 6. Exhibits and Reports on Form 8-K (a) Exhibits: None. (b) Reports on Form 8-K: No reports on Form 8-K have been filed during the quarter for which this report is filed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ASTRO-MED, INC. (Registrant) Date: December 2, 1996May 20, 1997 By /s/ A. W. Ondis -----------------------------____________________________ A. W. Ondis, Chairman (Principal Executive Officer) Date: December 2, 1996May 20, 1997 By /s/ Joseph P. O'Connell -----------------------------____________________________ Joseph P. O'Connell, Vice President and Treasurer (Principal Financial Officer) 10-8- SAFE HARBOR STATEMENT Statements which are not historical facts including statements about our expectations on new and existing products and opportunities, market growth, demand and acceptance of new and existing products are forward looking statements that involve risks and uncertainties. Those uncertainties include but are not limited to product demand and market acceptance risks; the impact of competitive products and pricing; delays or difficulties in developing, producing, testing and selling new products and technologies; capacity and supply constraints or difficulties; trade, legal, social and economic risks such as licensing, and trade restrictions, including those affecting international trade; and other risk factors listed from time to time in the Company's SEC reports including but not limited to the report on Form 10-Q for the quarter ended November 2, 1996. 11May 3, 1997. -9-